The natural history of primary progressive multiple sclerosis

Marcus Koch1, Elaine Kingwell, Peter Rieckmann

  • 1Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada. m.w.koch@neuro.umcg.nl

Neurology
|December 10, 2009
PubMed
Abstract

Insights

Predictors of slower disease progression in primary progressive multiple sclerosis (PPMS) were identified. Sensory onset symptoms and younger age at onset were linked to longer time to Expanded Disability Status Scale (EDSS) 6.0.

Area of Science:

  • Neurology
  • Clinical Research
  • Epidemiology

Background:

  • Primary progressive multiple sclerosis (PPMS) is an aggressive subtype of multiple sclerosis (MS) with no current treatments.
  • Previous studies suggested rapid disability progression in PPMS, but predictors were not well-defined.
  • This study updates analyses on a PPMS cohort to identify progression predictors.

Purpose of the Study:

  • To investigate predictors of disease progression in primary progressive multiple sclerosis.
  • To determine the influence of gender, age at onset, and onset symptoms on time to and age at Expanded Disability Status Scale (EDSS) 6.0.

Main Methods:

  • Retrospective cohort study of prevalent primary progressive multiple sclerosis cases.
  • Kaplan-Meier survival analyses and Cox regression models were employed.
  • Analysis focused on time to and age at Expanded Disability Status Scale (EDSS) 6.0.

Main Results:

  • Out of 5,779 MS patients, 552 (10%) had PPMS.
  • Median time to EDSS 6.0 was 14.0 years, reached at a median age of 58.6 years.
  • Sensory onset symptoms were associated with longer time to and older age at EDSS 6.0. Younger age at onset correlated with longer time to EDSS 6.0 but reaching it at a younger age.

Conclusions:

  • Sensory onset symptoms predict slower progression in PPMS, indicating longer time and older age to reach EDSS 6.0.
  • Younger age at disease onset also predicts longer time to EDSS 6.0, though the age at reaching this milestone is younger.
  • These findings identify key predictors for disease progression in PPMS, aiding in prognosis and management strategies.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...